Tissue-Resident Immune Cells in Human Aging

Abstract

Tissue-resident immune cells (TRICs) play a pivotal role in maintaining tissue homeostasis, orchestrating local immune surveillance, and modulating inflammatory responses throughout the human lifespan. With advancing age, the phenotype, function, and distribution of TRICs undergo profound alterations that significantly impact tissue integrity, susceptibility to infection, and the development of age-associated pathologies. This review synthesizes the current evidence on the epidemiology, mechanisms, clinical features, diagnosis, and management strategies related to TRICs in aging, offering insights into recent advances and guideline-based recommendations for clinicians and researchers.

Introduction

The immune system is traditionally categorized into innate and adaptive components; however, the concept of tissue-resident immune cells (TRICs) has revolutionized immunology by highlighting the diversity and specialization of local immune populations. These cells, including tissue-resident macrophages, dendritic cells, T cells, and innate lymphoid cells, are strategically positioned in virtually all organs, providing a first line of defense and contributing to tissue repair and remodeling. The aging process is characterized by immunosenescence and a chronic, low-grade inflammatory state termed \\"inflammaging\\", with TRICs being both mediators and targets of these changes. Understanding their dynamics in aging is crucial for addressing age-related vulnerability to infection, cancer, and degenerative diseases.

Epidemiology / Disease Burden

Population aging is a global phenomenon, with the proportion of individuals over 65 years projected to double by 2050. Age-related alterations in TRICs contribute to the increasing incidence of chronic inflammatory diseases, impaired wound healing, neurodegeneration, and malignancies in the elderly. Epidemiological studies have established associations between dysfunctional TRIC populations and the prevalence of diseases such as atherosclerosis, Alzheimer’s disease, and chronic lung disorders. The burden is further heightened by increased susceptibility to infections, reduced vaccine efficacy, and delayed tissue regeneration in older adults.

Pathophysiology

The pathophysiology of TRIC changes in aging encompasses both intrinsic and extrinsic mechanisms. Cellular senescence, DNA damage, epigenetic drift, and altered intercellular signaling contribute to functional decline. For example, aged tissue-resident macrophages exhibit impaired phagocytosis, decreased anti-inflammatory cytokine production, and increased secretion of pro-inflammatory mediators. In the skin, Langerhans cells decline in number and function, compromising barrier immunity. Similarly, brain-resident microglia adopt a pro-inflammatory phenotype, promoting neuroinflammation. These alterations are compounded by changes in the tissue microenvironment, including fibrosis, altered extracellular matrix composition, and dysregulated metabolic cues, all of which further drive TRIC dysfunction and tissue pathology.

Risk Factors

Several factors modulate the trajectory of TRIC aging. Genetic predisposition, chronic infections (notably cytomegalovirus), metabolic syndrome, and environmental stressors such as pollution and UV exposure accelerate immune aging. Lifestyle factors, including physical inactivity, poor nutrition, and chronic psychological stress, exacerbate TRIC dysfunction. Conversely, regular exercise, caloric moderation, and a balanced diet rich in antioxidants appear to preserve TRIC function and delay immunosenescence. Understanding individual risk profiles is essential for predicting and mitigating adverse outcomes associated with age-related TRIC alterations.

Clinical Features

The clinical manifestations of TRIC dysfunction in aging are multifaceted and organ-specific. Increased susceptibility to respiratory infections, persistent low-grade inflammation, impaired wound healing, and poor vaccine responses are hallmark features. In the central nervous system, altered microglial activity is implicated in cognitive decline and neurodegenerative disease progression. In the cardiovascular system, pro-inflammatory TRICs contribute to atherosclerotic plaque instability and vascular remodeling. Cutaneous manifestations include delayed healing, increased infection risk, and impaired barrier function. These features often overlap with comorbidities, complicating clinical assessment and intervention.

Diagnosis

Diagnosis of TRIC-related dysfunction relies on a combination of clinical evaluation, biomarker assessment, and advanced imaging or histopathological analysis. Flow cytometry and immunohistochemistry are widely used to quantify and characterize TRIC populations in tissue biopsies. Circulating markers of inflammation, such as IL-6, TNF-α, and C-reactive protein, are elevated in the context of inflammaging but lack tissue specificity. Emerging technologies, including single-cell RNA sequencing and mass cytometry, enable high-dimensional profiling of TRIC heterogeneity and functional states. These approaches are increasingly being integrated into clinical research protocols to facilitate biomarker discovery and patient stratification.

Treatment & Management

Management strategies for TRIC dysfunction in aging are primarily supportive and preventive, with an emphasis on reducing chronic inflammation and preserving tissue integrity. Lifestyle interventions, such as regular physical activity, weight management, and dietary optimization, are foundational. Pharmacologic agents targeting systemic inflammation, including statins and metformin, have shown promise in modulating TRIC activity. Immunomodulatory therapies, such as cytokine inhibitors or senolytics, are under investigation for their potential to restore TRIC function and mitigate age-related pathology. Supportive measures, including infection prophylaxis, timely vaccination, and wound care, remain critical in the clinical management of older adults.

Recent Advances / Emerging Therapies

Recent years have witnessed significant progress in the understanding and therapeutic manipulation of TRICs. Preclinical studies suggest that rejuvenation of tissue-resident macrophages through bone marrow transplantation or pharmacologic reprogramming can restore youthful immune function in animal models. Targeted delivery of senolytic agents to selectively eliminate senescent immune cells has demonstrated efficacy in reducing chronic inflammation and improving tissue regeneration. Advances in gene editing and cell therapy hold promise for correcting genetic and epigenetic defects in TRICs. These emerging modalities are poised to transform the management of age-related immune dysfunction, pending validation in clinical trials.

Guideline Recommendations

Current guidelines emphasize a holistic approach to the care of older adults, incorporating assessment and management of immune health as a core component. Regular screening for chronic diseases, vaccination, management of comorbidities, and promotion of healthy lifestyle behaviors are recommended. Consensus guidelines from geriatric and immunology societies advocate for the integration of biomarker-driven risk assessment and personalized interventions targeting immune aging. Clinicians are encouraged to remain updated on advances in TRIC-targeted therapies and to consider enrollment of eligible patients in clinical trials evaluating novel immunomodulatory agents.

Conclusion

Tissue-resident immune cells are central to the maintenance of tissue homeostasis and immune competence in aging humans. Their dysregulation contributes to a spectrum of age-associated diseases, representing both a challenge and an opportunity for therapeutic intervention. Ongoing research into the biology, diagnosis, and manipulation of TRICs is expanding the therapeutic armamentarium available to clinicians, with the ultimate goal of enhancing healthspan and quality of life for the aging population.